DOP2016000156A - Composiciones farmacã¿uticas que comprenden azd9291. - Google Patents

Composiciones farmacã¿uticas que comprenden azd9291.

Info

Publication number
DOP2016000156A
DOP2016000156A DO2016000156A DO2016000156A DOP2016000156A DO P2016000156 A DOP2016000156 A DO P2016000156A DO 2016000156 A DO2016000156 A DO 2016000156A DO 2016000156 A DO2016000156 A DO 2016000156A DO P2016000156 A DOP2016000156 A DO P2016000156A
Authority
DO
Dominican Republic
Prior art keywords
azd9291
pharmaceutical compositions
pharmaceutical
compositions
dimethylaminoethy
Prior art date
Application number
DO2016000156A
Other languages
English (en)
Inventor
David Wilson
Cindy Finnie
Steven Anthony Raw
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50191689&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DOP2016000156(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of DOP2016000156A publication Critical patent/DOP2016000156A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

LA PRESENTE INVENCIÿN SE RELACIONA CON COMPOSICIONES FARMACÿUTICAS ADECUADAS PARA LA ADMINISTRACIÿN ORAL, Y MÁS PARTICULARMENTE CON COMPOSICIONES FARMACÿUTICAS, INCLUYENDO COMPOSICIONES DE TABLETAS FARMACÿUTICAS, QUE CONTIENEN N (2 {2 DIMETILAMINOETIL-METILAMINO}-4-METOXI-5-{[4-(1-METILINDOL-3-IL)PIRIMIDIN-2-IL]AMINO}FENIL)PROP-2-ENAMIDA ("AZD9291") O UNA SAL FARMACÿUTICAMENTE ACEPTABLE DEL MISMO, EN DONDE TALES COMPOSICIONES COMPRENDEN UNA CIERTA CANTIDAD DE CELULOSA MICROCRISTALINA Y AL MENOS OTRO DILUYENTE FARMACÿUTICO.
DO2016000156A 2014-01-02 2016-06-22 Composiciones farmacã¿uticas que comprenden azd9291. DOP2016000156A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1400034.3A GB201400034D0 (en) 2014-01-02 2014-01-02 Pharmaceutical Compositions comprising AZD9291

Publications (1)

Publication Number Publication Date
DOP2016000156A true DOP2016000156A (es) 2016-08-15

Family

ID=50191689

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2016000156A DOP2016000156A (es) 2014-01-02 2016-06-22 Composiciones farmacã¿uticas que comprenden azd9291.

Country Status (37)

Country Link
US (4) US10183020B2 (es)
EP (1) EP3089741B1 (es)
JP (1) JP6588915B2 (es)
KR (1) KR102336378B1 (es)
CN (2) CN105848647B (es)
AR (1) AR098989A1 (es)
AU (1) AU2015204218B2 (es)
CA (1) CA2933403C (es)
CL (1) CL2016001609A1 (es)
CR (1) CR20160310A (es)
CY (1) CY1124848T1 (es)
DK (1) DK3089741T3 (es)
DO (1) DOP2016000156A (es)
EA (1) EA034243B9 (es)
ES (1) ES2873226T3 (es)
GB (1) GB201400034D0 (es)
GT (1) GT201600142A (es)
HK (1) HK1225655A1 (es)
HR (1) HRP20210749T1 (es)
HU (1) HUE054344T2 (es)
IL (1) IL246186B (es)
LT (1) LT3089741T (es)
MX (1) MX367358B (es)
MY (1) MY183536A (es)
NI (1) NI201600098A (es)
NZ (1) NZ721298A (es)
PE (1) PE20161170A1 (es)
PH (1) PH12016501310A1 (es)
PL (1) PL3089741T3 (es)
PT (1) PT3089741T (es)
RS (1) RS61927B1 (es)
SG (1) SG11201605339QA (es)
SI (1) SI3089741T1 (es)
TW (1) TWI702953B (es)
UY (1) UY35933A (es)
WO (1) WO2015101791A1 (es)
ZA (1) ZA201605300B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201400034D0 (en) * 2014-01-02 2014-02-19 Astrazeneca Ab Pharmaceutical Compositions comprising AZD9291
MX2018013413A (es) 2016-05-26 2019-06-06 Zeno Royalties & Milestones Llc Compuestos inhibidores de egfr.
CN108057036B (zh) * 2016-11-07 2023-06-13 正大天晴药业集团股份有限公司 一种egfr抑制剂的固体药物组合物
CN107176954B (zh) * 2017-06-02 2019-01-11 无锡双良生物科技有限公司 一种egfr抑制剂的药用盐及其晶型、制备方法和应用
CN110013468B (zh) * 2018-01-09 2022-02-18 北京福元医药股份有限公司 一种azd9291氘代衍生物药物制剂
WO2019138346A1 (en) * 2018-01-10 2019-07-18 Alembic Pharmaceuticals Limited Pharmaceutical composition of osimertinib
AU2019219304A1 (en) 2018-02-12 2020-09-24 Astrazeneca Ab Osimertinib for use in the treatment of non-small cell lung cancer
EP3758708A1 (en) * 2018-03-01 2021-01-06 AstraZeneca AB Pharmaceutical compositions comprising (2s)--{(1s)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide
KR102511672B1 (ko) * 2018-03-23 2023-03-17 우시 상량 바이오테크놀로지 씨오., 엘티디. 의약 조성물, 그 제조방법 및 사용
KR20200043618A (ko) 2018-10-18 2020-04-28 주식회사유한양행 아미노피리미딘 유도체 또는 이의 염을 포함하는 경구투여용 약학 조성물
MA55508A (fr) 2019-03-29 2022-02-09 Astrazeneca Ab Osimertinib destiné à être utilisé dans le traitement du cancer du poumon non à petites cellules
US20210161897A1 (en) 2019-11-12 2021-06-03 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
MX2022008874A (es) 2020-01-20 2022-08-11 Astrazeneca Ab Inhibidores de la tirosina cinasa del receptor del factor de creciminto epidermico para el tratamiento del cancer.
US20210369709A1 (en) 2020-05-27 2021-12-02 Astrazeneca Ab EGFR TKIs FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER
WO2023187037A1 (en) 2022-03-31 2023-10-05 Astrazeneca Ab Epidermal growth factor receptor (egfr) tyrosine kinase inhibitors in combination with an akt inhibitor for the treatment of cancer
WO2023209084A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Condensed bicyclic heteroaromatic compounds and their use in the treatment of cancer
US20240116926A1 (en) 2022-04-28 2024-04-11 Astrazeneca Ab Heteroaromatic compounds
WO2023209088A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds and their use in the treatment of cancer
WO2023209090A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds and their application in the treatment of cancer
WO2024002938A1 (en) 2022-06-27 2024-01-04 Astrazeneca Ab Combinations involving epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
WO2024008929A1 (en) 2022-07-08 2024-01-11 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors in combination with hgf-receptor inhibitors for the treatment of cancer

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL110376A (en) * 1993-08-02 1998-08-16 Bristol Myers Squibb Co Pharmaceutical preparations containing iftroban and methods for their preparation
SE9802973D0 (sv) * 1998-09-03 1998-09-03 Astra Ab Immediate release tablet
JP4802436B2 (ja) * 2000-04-12 2011-10-26 Ｍｓｄ株式会社 口腔内崩壊型組成物及び口腔内崩壊型製剤
US6881737B2 (en) 2001-04-11 2005-04-19 Amgen Inc. Substituted triazinyl acrylamide derivatives and methods of use
MY135609A (en) 2002-02-26 2008-05-30 Astrazeneca Ab Pharmaceutical formulation of iressa comprising a water-soluble cellulose derivative
EP1799190A1 (en) * 2004-10-05 2007-06-27 Altana Pharma AG Oral pharmaceutical preparation for proton pump antagonists
ES2279715B1 (es) * 2005-12-26 2008-06-01 Laboratorios Lesvi, S.L. Formulacion oral de olanzapina.
JP5133071B2 (ja) * 2006-02-09 2013-01-30 第一三共株式会社 抗癌医薬組成物
JP5576922B2 (ja) * 2006-04-20 2014-08-20 信越化学工業株式会社 腸溶性固体分散体を含んでなる固形製剤
EP2170062A4 (en) * 2007-07-12 2010-12-29 Tragara Pharmaceuticals Inc METHOD AND COMPOSITIONS FOR THE TREATMENT OF CANCER DISORDERS, TUMORS AND TUMOR-DISORDED DISEASES
EP2696857A1 (en) 2011-04-11 2014-02-19 Alfred E. Tiefenbacher (GmbH & Co. KG) Pharmaceutical composition comprising bosentan
KR101317809B1 (ko) 2011-06-07 2013-10-16 한미약품 주식회사 암세포의 성장을 억제하는 아마이드 유도체 및 비금속염 활택제를 포함하는 약학 조성물
PL3686194T3 (pl) * 2011-07-27 2022-01-17 Astrazeneca Ab Związki 2-(2,4,5-podstawione-anilino)pirymidynowe
EP3181128B1 (en) * 2012-01-13 2023-03-08 XSpray Pharma AB (publ) Nilotinib pharmaceuticalcomposition
WO2013160916A1 (en) 2012-04-25 2013-10-31 Hetero Research Foundation Sunitinib malate solid dispersion
GB201400034D0 (en) * 2014-01-02 2014-02-19 Astrazeneca Ab Pharmaceutical Compositions comprising AZD9291

Also Published As

Publication number Publication date
IL246186B (en) 2020-07-30
CY1124848T1 (el) 2022-11-25
KR102336378B1 (ko) 2021-12-08
CN114712362A (zh) 2022-07-08
SI3089741T1 (sl) 2021-08-31
CA2933403A1 (en) 2015-07-09
EA034243B1 (ru) 2020-01-21
MX2016008744A (es) 2016-09-08
JP2017501201A (ja) 2017-01-12
TW201609101A (zh) 2016-03-16
CN105848647B (zh) 2022-04-26
EA201691242A1 (ru) 2016-12-30
ES2873226T3 (es) 2021-11-03
CA2933403C (en) 2022-03-29
GT201600142A (es) 2019-08-12
US20220395502A1 (en) 2022-12-15
CL2016001609A1 (es) 2016-12-09
IL246186A0 (en) 2016-07-31
AU2015204218A1 (en) 2016-07-07
EP3089741A1 (en) 2016-11-09
AU2015204218B2 (en) 2017-06-15
PL3089741T3 (pl) 2021-09-27
MY183536A (en) 2021-02-25
HUE054344T2 (hu) 2021-08-30
KR20160101720A (ko) 2016-08-25
RS61927B1 (sr) 2021-06-30
EP3089741B1 (en) 2021-03-10
US20160324854A1 (en) 2016-11-10
LT3089741T (lt) 2021-06-10
GB201400034D0 (en) 2014-02-19
AR098989A1 (es) 2016-06-22
CR20160310A (es) 2016-09-23
HRP20210749T1 (hr) 2021-06-25
NI201600098A (es) 2016-12-20
CN105848647A (zh) 2016-08-10
PE20161170A1 (es) 2016-11-24
DK3089741T3 (da) 2021-06-07
US20190111057A1 (en) 2019-04-18
SG11201605339QA (en) 2016-07-28
HK1225655A1 (zh) 2017-09-15
US10183020B2 (en) 2019-01-22
TWI702953B (zh) 2020-09-01
PT3089741T (pt) 2021-06-11
JP6588915B2 (ja) 2019-10-09
UY35933A (es) 2015-07-31
PH12016501310A1 (en) 2016-09-14
ZA201605300B (en) 2022-10-26
MX367358B (es) 2019-08-16
EA034243B9 (ru) 2020-04-10
NZ721298A (en) 2017-10-27
WO2015101791A1 (en) 2015-07-09
US20200360378A1 (en) 2020-11-19

Similar Documents

Publication Publication Date Title
DOP2016000156A (es) Composiciones farmacã¿uticas que comprenden azd9291.
DOP2020000102A (es) Compuestos útiles para inhibir a cdk7
BR112018010018A2 (pt) moduladores de ror-gama
NI201700101A (es) Composiciones farmacéuticas que comprenden n - (3, 5 - dimetoxifenil) - n'- (1-metiletil) - n - [3-(1-metil-1h-pirazol-4-il) quinoxalina-6-il]etano-1,2-diamina
EA201992116A1 (ru) Фармацевтические составы флороглюцинола и триметилфлороглюцинола
CR20180253A (es) Composiciones terapéuticas para el tratamiento del virus de unmunodeficiencia humana
EA201792592A1 (ru) Фармацевтические препараты, содержащие тенофовир и эмтрицитабин
DOP2016000254A (es) Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso.
BR112018073951A2 (pt) forma cristalina inovadora de n-[5-(3,5-difluoro-benzil)-1h-indazol-3-il]-4-(4-metil-piperazin-1-il)-2-(tetra-hidro-piran-4-ilamino)-benzamida
EA201890532A1 (ru) Новые аннелированные бензамиды
BR112017004948A2 (pt) formulação farmacêutica.
EA201890534A1 (ru) Новые аннелированные феноксиацетамиды
UY35890A (es) Uso de laquinimod para retrasar la progresión de la enfermedad de huntington
CO2017004382A2 (es) Composiciones farmacéuticas que comprenden lobeglitazona para administración oral
BR112016026422A2 (pt) solução farmacêutica compreendendo dopamina para uso no tratamento da doença de parkinson
EA201991288A1 (ru) Фармацевтические композиции на основе дабигатрана
PH12016502527A1 (en) Stabilized desmopressin
EA201890477A1 (ru) Инкапсулированная композиция финголимода
AR113817A1 (es) Compuestos útiles para inhibir a cdk7
CO2018005367A2 (es) Composición farmacéutica que contiene, como ingrediente activo, derivado de 7-azaindolin-2-ona o sal farmacéuticamente aceptable del mismo campo técnico
MX2020004403A (es) Composiciones farmaceuticas que comprenden safinamida.
MX2014008984A (es) Proceso de obtencion y composicion farmaceutica de fenofibrato capsulas como agente regulador de lipidos para su administracion oral.
MX2018007272A (es) Composicion farmaceutica de liberacion pulsatil que comprende naftazona o una de sus sales.
UA113237U (uk) Фармацевтична комбінація ацеклофенаку і снодійного або заспокійливого компонента
AR100175A1 (es) Inhibidores de autotaxina